ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

$59.22 -0.50 (-0.84 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$59.22
Today's Range$58.76 - $59.74
52-Week Range$42.23 - $74.70
Volume56,797 shs
Average Volume115,380 shs
Market Capitalization$683.73 million
P/E Ratio94.00
Dividend YieldN/A
Beta2.79

About ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals logoANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:ANIP
CUSIPN/A
Phone+1-218-6343500

Debt

Debt-to-Equity Ratio0.83%
Current Ratio3.45%
Quick Ratio2.39%

Price-To-Earnings

Trailing P/E Ratio94
Forward P/E Ratio16.50
P/E GrowthN/A

Sales & Book Value

Annual Sales$128.62 million
Price / Sales5.36
Cash Flow$4.51 per share
Price / Cash13.13
Book Value$14.63 per share
Price / Book4.05

Profitability

Trailing EPS$0.63
Net Income$3.93 million
Net Margins4.45%
Return on Equity22.40%
Return on Assets11.14%

Miscellaneous

Employees143
Outstanding Shares11,650,000

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals Inc (NASDAQ:ANIP) posted its quarterly earnings data on Thursday, November, 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.12. The specialty pharmaceutical company had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The business's revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.09 earnings per share. View ANI Pharmaceuticals' Earnings History.

Where is ANI Pharmaceuticals' stock going? Where will ANI Pharmaceuticals' stock price be in 2018?

3 Wall Street analysts have issued 1 year price objectives for ANI Pharmaceuticals' shares. Their predictions range from $56.00 to $80.00. On average, they anticipate ANI Pharmaceuticals' share price to reach $71.00 in the next year. View Analyst Ratings for ANI Pharmaceuticals.

What are Wall Street analysts saying about ANI Pharmaceuticals stock?

Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (1/2/2018)
  • 2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)

Who are some of ANI Pharmaceuticals' key competitors?

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the folowing people:

  • Robert E. Brown Jr., Independent Chairman of the Board (Age 66)
  • Arthur S. Przybyl, President, Chief Executive Officer, Director (Age 60)
  • Stephen P. Carey, Chief Financial Officer, Vice President (Age 46)
  • James G. Marken, Vice President - Operations (Age 54)
  • Mark J. Ginski Ph.D., Vice President of Corticotropin Product Development
  • Karen Quinn Ph.D., Vice President - Corticotropin Regulatory Affairs
  • Robert W. Schrepfer, Vice President - New Business Development and Contract Manufacturing (Age 45)
  • Fred E. Holubow, Independent Director (Age 78)
  • Tracy L. Marshbanks Ph.D., Independent Director (Age 53)
  • Thomas A. Penn, Independent Director (Age 71)

Who owns ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.00%), Deutsche Bank AG (1.37%), First Manhattan Co. (1.25%), Cortina Asset Management LLC (0.81%), Allianz Asset Management GmbH (0.80%) and Geode Capital Management LLC (0.66%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl and Robert W Schrepfer. View Institutional Ownership Trends for ANI Pharmaceuticals.

Who sold ANI Pharmaceuticals stock? Who is selling ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Allianz Asset Management GmbH, First Manhattan Co., Renaissance Technologies LLC, Cadence Capital Management LLC, Guggenheim Capital LLC, Goldman Sachs Group Inc., 1492 Capital Management LLC and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for ANI Pharmaceuticals.

Who bought ANI Pharmaceuticals stock? Who is buying ANI Pharmaceuticals stock?

ANI Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Triarii Capital Management LP, Nexthera Capital LP, Algert Global LLC, Schwab Charles Investment Management Inc., Two Sigma Investments LP, Cornerstone Capital Management Holdings LLC. and Cornercap Investment Counsel Inc.. View Insider Buying and Selling for ANI Pharmaceuticals.

How do I buy ANI Pharmaceuticals stock?

Shares of ANI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANI Pharmaceuticals stock can currently be purchased for approximately $59.22.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $683.73 million and generates $128.62 million in revenue each year. The specialty pharmaceutical company earns $3.93 million in net income (profit) each year or $0.63 on an earnings per share basis. ANI Pharmaceuticals employs 143 workers across the globe.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 W Main St, BAUDETTE, MN 56623-2467, United States. The specialty pharmaceutical company can be reached via phone at +1-218-6343500 or via email at [email protected]


MarketBeat Community Rating for ANI Pharmaceuticals (ANIP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  219 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  401
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ANI Pharmaceuticals (NASDAQ:ANIP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.672.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $71.00$71.00$67.33$65.33
Price Target Upside: 11.62% upside11.62% upside12.02% upside50.26% upside

ANI Pharmaceuticals (NASDAQ:ANIP) Consensus Price Target History

Price Target History for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/29/2017Canaccord GenuitySet Price TargetBuy$77.00LowView Rating Details
7/4/2017GuggenheimReiterated RatingBuy$80.00LowView Rating Details
5/6/2017Roth CapitalSet Price TargetHold$56.00LowView Rating Details
8/5/2016OppenheimerBoost Price TargetOutperform$65.00 -> $71.00N/AView Rating Details
7/19/2016CitigroupUpgradeOutperform$65.00N/AView Rating Details
6/22/2016Raymond James FinancialInitiated CoverageStrong-Buy$68.00N/AView Rating Details
5/24/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

ANI Pharmaceuticals (NASDAQ:ANIP) Earnings History and Estimates Chart

Earnings by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ ANIP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017$0.99$1.11$48.12 million$48.16 millionViewN/AView Earnings Details
8/3/2017Q2 2017$0.79$0.98$43.20 million$44.80 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.70$0.74$39.63 million$36.60 millionViewListenView Earnings Details
3/2/2017Q4 2016$1.09$0.84$40.98 million$38.20 millionViewListenView Earnings Details
11/3/2016Q316$1.08$1.09$34.34 million$38.53 millionViewN/AView Earnings Details
8/4/2016Q216$0.77$1.11$27.63 million$31.30 millionViewN/AView Earnings Details
5/5/2016Q116$0.64$0.76$21.03 million$20.60 millionViewN/AView Earnings Details
2/23/2016Q415$0.60$0.52$18.13 million$18.04 millionViewN/AView Earnings Details
11/3/2015Q315$0.63$0.80$21.37 million$20.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.54$0.31$20.30 million$19.52 millionViewN/AView Earnings Details
5/5/2015Q115$0.56$0.53$19.86 million$18.80 millionViewN/AView Earnings Details
2/19/2015Q414$0.57$0.60$17.98 million$21.04 millionViewN/AView Earnings Details
11/3/2014Q314$0.43$0.59$14.60 million$17.40 millionViewN/AView Earnings Details
8/4/2014Q214($0.01)($0.21)$7.95 million$6.60 millionViewN/AView Earnings Details
5/5/2014Q115$0.32$0.33$11.40 million$10.90 millionViewN/AView Earnings Details
2/27/2014Q414$0.35$5.32 million$10.53 millionViewN/AView Earnings Details
2/18/2014Q4 2013$0.23$0.35$9.18 million$10.53 millionViewN/AView Earnings Details
11/7/2013$0.16$7.84 millionViewN/AView Earnings Details
8/9/2013Q2 2013($1.26)$6.15 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.54)ViewN/AView Earnings Details
3/1/2013Q4 2012($0.96)ViewN/AView Earnings Details
11/8/2012Q312($0.36)($0.27)ViewN/AView Earnings Details
8/1/2012Q2 2012($2.46)($2.18)ViewN/AView Earnings Details
5/8/2012Q1 2012($2.52)($3.24)ViewN/AView Earnings Details
3/13/2012Q4 2011($3.96)($2.16)ViewN/AView Earnings Details
11/9/2011Q3 2011($5.04)($4.39)ViewN/AView Earnings Details
7/25/2011Q2 2011($6.48)($5.76)ViewN/AView Earnings Details
5/10/2011Q1 2011($5.40)($7.20)ViewN/AView Earnings Details
3/16/2011Q4 2010($5.40)($6.48)ViewN/AView Earnings Details
11/12/2010Q3 2010($5.04)($5.76)ViewN/AView Earnings Details
8/12/2010Q2 2010($3.96)($6.12)ViewN/AView Earnings Details
5/14/2010Q1 2010($3.96)($6.84)ViewN/AView Earnings Details
11/9/2009Q3 2009($5.76)($5.79)ViewN/AView Earnings Details
8/7/2009Q2 2009($5.40)($6.12)ViewN/AView Earnings Details
5/11/2009Q1 2009($5.76)($5.40)ViewN/AView Earnings Details
3/16/2009Q4 2008($8.64)($1.80)ViewN/AView Earnings Details
11/10/2008Q3 2008($7.20)($8.64)ViewN/AView Earnings Details
8/11/2008Q2 2008($5.40)($7.92)ViewN/AView Earnings Details
5/9/2008Q1 2008($4.32)($4.68)ViewN/AView Earnings Details
3/17/2008Q4 2007($2.16)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

ANI Pharmaceuticals (NASDAQ:ANIP) Earnings Estimates

Current Year EPS Consensus Estimate: $3.59 EPS
Next Year EPS Consensus Estimate: $4.35 EPS

Dividends

Dividend History for ANI Pharmaceuticals (NASDAQ:ANIP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ANI Pharmaceuticals (NASDAQ ANIP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 31.80%
Institutional Ownership Percentage: 53.51%
Insider Trades by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)
Institutional Ownership by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ ANIP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2016Arthur PrzybylInsiderSell37,455$66.97$2,508,361.35200,788View SEC Filing  
8/8/2016Robert W SchrepferVPSell12,500$67.06$838,250.0017,362View SEC Filing  
12/18/2015James G MarkenVPSell3,500$43.26$151,410.0045,983View SEC Filing  
11/12/2015Arthur PrzybylCEOBuy2,500$40.95$102,375.00145,195View SEC Filing  
3/19/2015James G MarkenVPSell15,000$66.50$997,500.00View SEC Filing  
9/15/2014Ross J ManganoDirectorBuy3,000$27.49$82,470.00View SEC Filing  
9/9/2014Arthur PrzybylCEOBuy1,000$26.50$26,500.00View SEC Filing  
6/18/2014James G MarkenVPSell5,000$34.28$171,400.00View SEC Filing  
5/8/2014Tracy MarshbanksDirectorSell1,381$30.02$41,457.62View SEC Filing  
5/7/2014Ross ManganoDirectorBuy2,000$30.38$60,760.0023,914View SEC Filing  
3/21/2014Tracy MarshbanksDirectorSell21,767$31.42$683,919.14View SEC Filing  
3/20/2014Meridian Venture Partners Ii Lmajor shareholderSell20,922$32.12$672,014.64View SEC Filing  
3/19/2014Tracy MarshbanksDirectorSell25,358$33.68$854,057.44View SEC Filing  
3/18/2014Meridian Venture Partners Ii Lmajor shareholderSell60,540$34.07$2,062,597.80View SEC Filing  
3/13/2014Meridian Venture Partners Ii Lmajor shareholderSell87,723$32.48$2,849,243.04View SEC Filing  
11/7/2013Ross J ManganoDirectorBuy9,000$11.27$101,430.00View SEC Filing  
8/20/2013Ross J ManganoDirectorBuy10,000$7.47$74,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ANI Pharmaceuticals (NASDAQ ANIP) News Headlines

Source:
DateHeadline
Investors Are Undervaluing ANI Pharmaceuticals Inc (NASDAQ:ANIP) By 39.62%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing ANI Pharmaceuticals Inc (NASDAQ:ANIP) By 39.62%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - February 14 at 9:27 AM
ANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of "Hold" from BrokeragesANI Pharmaceuticals Inc (ANIP) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 13 at 1:38 AM
 Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) Will Post Earnings of $1.09 Per Share Analysts Anticipate ANI Pharmaceuticals Inc (ANIP) Will Post Earnings of $1.09 Per Share
www.americanbankingnews.com - February 6 at 9:12 PM
ANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $1.09 Per ShareANI Pharmaceuticals Inc (ANIP) Expected to Announce Earnings of $1.09 Per Share
www.americanbankingnews.com - January 21 at 1:16 AM
ANI Pharmaceuticals Inc (ANIP) Given Consensus Recommendation of "Buy" by AnalystsANI Pharmaceuticals Inc (ANIP) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 19 at 1:32 AM
ANI Pharmaceuticals (ANIP) Stock Rating Upgraded by BidaskClubANI Pharmaceuticals (ANIP) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 6 at 12:30 PM
INC Research (INCR) versus ANI Pharmaceuticals (ANIP) Head to Head ComparisonINC Research (INCR) versus ANI Pharmaceuticals (ANIP) Head to Head Comparison
www.americanbankingnews.com - January 4 at 7:30 PM
$1.09 EPS Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter$1.09 EPS Expected for ANI Pharmaceuticals Inc (ANIP) This Quarter
www.americanbankingnews.com - January 4 at 3:28 AM
Top-Rated Stocks: ANI Pharmaceuticals Sees Composite Rating Climb To 97Top-Rated Stocks: ANI Pharmaceuticals Sees Composite Rating Climb To 97
finance.yahoo.com - January 3 at 11:00 AM
ANI Pharmaceuticals (ANIP) Lowered to "Hold" at Zacks Investment ResearchANI Pharmaceuticals (ANIP) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 2 at 5:56 PM
ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : January 1, 2018ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : January 1, 2018
finance.yahoo.com - January 1 at 10:11 AM
ANI Pharmaceuticals acquires four AstraZeneca NDAs - Seeking AlphaANI Pharmaceuticals acquires four AstraZeneca NDAs - Seeking Alpha
seekingalpha.com - December 31 at 3:32 PM
ANI Pharmaceuticals (ANIP) Given a $77.00 Price Target by Canaccord Genuity AnalystsANI Pharmaceuticals (ANIP) Given a $77.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - December 29 at 6:32 PM
ANI Pharma (ANIP) Acquires US Rights to Four NDAs from AstraZeneca (AZN) for $46.5M - StreetInsider.comANI Pharma (ANIP) Acquires US Rights to Four NDAs from AstraZeneca (AZN) for $46.5M - StreetInsider.com
www.streetinsider.com - December 29 at 3:30 PM
ANI Pharmaceuticals Inc (ANIP) Receives Consensus Recommendation of "Buy" from AnalystsANI Pharmaceuticals Inc (ANIP) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 25 at 1:57 AM
BidaskClub Downgrades ANI Pharmaceuticals (ANIP) to HoldBidaskClub Downgrades ANI Pharmaceuticals (ANIP) to Hold
www.americanbankingnews.com - December 23 at 4:14 PM
How Do Analysts See ANI Pharmaceuticals Inc (NASDAQ:ANIP) Performing Over The Next Few Years?How Do Analysts See ANI Pharmaceuticals Inc (NASDAQ:ANIP) Performing Over The Next Few Years?
finance.yahoo.com - December 22 at 10:11 AM
ANI Pharmaceuticals (ANIP) Stock Rating Lowered by ValuEngineANI Pharmaceuticals (ANIP) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 20 at 10:10 PM
 Brokerages Expect ANI Pharmaceuticals Inc (ANIP) Will Announce Quarterly Sales of $52.49 Million Brokerages Expect ANI Pharmaceuticals Inc (ANIP) Will Announce Quarterly Sales of $52.49 Million
www.americanbankingnews.com - December 20 at 8:38 AM
ETFs with exposure to ANI Pharmaceuticals, Inc. : December 18, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:29 PM
ANI Pharmaceuticals Inc (undefined:ANIP): Should The Recent EPS Drop Worry You?ANI Pharmaceuticals Inc (undefined:ANIP): Should The Recent EPS Drop Worry You?
finance.yahoo.com - December 13 at 3:30 PM
Head-To-Head Survey: ANI Pharmaceuticals (ANIP) versus Alkermes (ALKS)Head-To-Head Survey: ANI Pharmaceuticals (ANIP) versus Alkermes (ALKS)
www.americanbankingnews.com - December 10 at 7:20 PM
Canaccord Genuity Reiterates "$75.00" Price Target for ANI Pharmaceuticals (ANIP)Canaccord Genuity Reiterates "$75.00" Price Target for ANI Pharmaceuticals (ANIP)
www.americanbankingnews.com - December 10 at 7:16 AM
Is It The Right Time To Buy ANI Pharmaceuticals Inc (ANIP)?Is It The Right Time To Buy ANI Pharmaceuticals Inc (ANIP)?
finance.yahoo.com - December 4 at 3:29 PM
 Analysts Expect ANI Pharmaceuticals, Inc. (ANIP) Will Announce Quarterly Sales of $52.49 Million Analysts Expect ANI Pharmaceuticals, Inc. (ANIP) Will Announce Quarterly Sales of $52.49 Million
www.americanbankingnews.com - December 2 at 8:50 AM
Stocks To Watch: ANI Pharmaceuticals Sees Relative Strength Rating Rise To 93Stocks To Watch: ANI Pharmaceuticals Sees Relative Strength Rating Rise To 93
finance.yahoo.com - December 1 at 6:03 PM
ANI Pharmaceuticals, Inc. (ANIP) Receives Consensus Recommendation of "Buy" from BrokeragesANI Pharmaceuticals, Inc. (ANIP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 30 at 1:52 AM
ETFs with exposure to ANI Pharmaceuticals, Inc. : November 27, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : November 27, 2017
finance.yahoo.com - November 27 at 3:20 PM
ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7% - NasdaqANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7% - Nasdaq
www.nasdaq.com - November 27 at 11:25 AM
ANI Pharmaceuticals, Inc. (ANIP) Stock Rating Lowered by ValuEngineANI Pharmaceuticals, Inc. (ANIP) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - November 26 at 2:16 PM
ANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by ValuEngineANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - November 25 at 6:46 AM
Ani Pharmaceuticals: Potential Buyout Gains Credence - ANI ... - Seeking AlphaAni Pharmaceuticals: Potential Buyout Gains Credence - ANI ... - Seeking Alpha
seekingalpha.com - November 21 at 3:52 AM
ANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by TheStreetANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by TheStreet
www.americanbankingnews.com - November 18 at 8:06 AM
ETFs with exposure to ANI Pharmaceuticals, Inc. : November 16, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : November 16, 2017
finance.yahoo.com - November 16 at 4:09 PM
Zacks: Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Quarterly Sales of $52.49 MillionZacks: Brokerages Anticipate ANI Pharmaceuticals, Inc. (ANIP) Will Post Quarterly Sales of $52.49 Million
www.americanbankingnews.com - November 13 at 1:20 AM
ANI Pharmaceuticals (ANIP) versus Its Competitors Head-To-Head ComparisonANI Pharmaceuticals (ANIP) versus Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - November 11 at 1:28 AM
ANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by Zacks Investment ResearchANI Pharmaceuticals, Inc. (ANIP) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 7 at 3:52 PM
Critical Review: ANI Pharmaceuticals (ANIP) versus Its PeersCritical Review: ANI Pharmaceuticals (ANIP) versus Its Peers
www.americanbankingnews.com - November 7 at 11:44 AM
ETFs with exposure to ANI Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to ANI Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 6 at 4:42 PM
ANI Pharmaceuticals, Inc. (ANIP) Given Average Rating of "Buy" by BrokeragesANI Pharmaceuticals, Inc. (ANIP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 5 at 1:32 AM
ANI Pharmaceuticals, Inc. (ANIP) Upgraded at ValuEngineANI Pharmaceuticals, Inc. (ANIP) Upgraded at ValuEngine
www.americanbankingnews.com - November 4 at 4:42 PM
ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017ANI Pharmaceuticals, Inc. :ANIP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 4:03 PM
ANI Pharma Narrows 2017 Guidance - Quick FactsANI Pharma Narrows 2017 Guidance - Quick Facts
www.rttnews.com - November 3 at 9:27 AM
Edited Transcript of ANIP earnings conference call or presentation 2-Nov-17 2:30pm GMTEdited Transcript of ANIP earnings conference call or presentation 2-Nov-17 2:30pm GMT
finance.yahoo.com - November 3 at 9:27 AM
ANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord GenuityANI Pharmaceuticals, Inc. (ANIP) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - November 2 at 10:30 PM
ANI Pharmaceuticals, Inc. Earnings Advance 45% In Q3ANI Pharmaceuticals, Inc. Earnings Advance 45% In Q3
www.nasdaq.com - November 2 at 4:21 PM
ANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year GuidanceANI Pharmaceuticals Reports Record Third Quarter and Year-To-Date 2017 Results and Narrows Full Year Guidance
finance.yahoo.com - November 2 at 4:20 PM
ANI posts 3Q profitANI posts 3Q profit
finance.yahoo.com - November 2 at 4:20 PM
ANI Pharmaceuticals, Inc. (ANIP) Issues Quarterly  Earnings ResultsANI Pharmaceuticals, Inc. (ANIP) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 2 at 3:07 PM
ANI Pharmaceuticals, Inc. (ANIP) Issues FY17 Earnings GuidanceANI Pharmaceuticals, Inc. (ANIP) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 2 at 9:22 AM

SEC Filings

ANI Pharmaceuticals (NASDAQ:ANIP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ANI Pharmaceuticals (NASDAQ:ANIP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ANI Pharmaceuticals (NASDAQ ANIP) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.